Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Webinar on Monday, September 13, 2021 at 12:00 p.m. ET -
Montreal, Canada – August 31, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will host a key opinion leader (KOL) webinar to discuss tesamorelin for the treatment of NASH on Monday, September 13, 2021 at 12:00 p.m. Eastern Time.
To register for the webinar, please click here.
The webinar will feature a fireside chat with KOLs Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, Director of Hepatology, and Professor of Medicine at University of California at San Diego School, Stephen A. Harrison, MD, FACP, FAASLD, Radcliffe Department of Medicine, University of Oxford, and Steven K. Grinspoon, MD. Harvard Medical School, who will discuss the current treatment landscape and unmet medical need in treating patients with NASH, as well as discuss Theratechnologies’ Phase 3 development program evaluating tesamorelin for the treatment of NASH.
Drs. Loomba, Harrison, and Grinspoon and Theratechnologies’ management team will be available to answer questions from the audience following the fireside chat.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov
For media and investor relations inquiries:
Senior Director, Investor Relations
ir@theratech.com
617-356-1009